144 related articles for article (PubMed ID: 31705876)
1. E2F1/IGF-1R Loop Contributes to BRAF Inhibitor Resistance in Melanoma.
Liu X; Mi J; Qin H; Li Z; Chai J; Li M; Wu J; Xu J
J Invest Dermatol; 2020 Jun; 140(6):1295-1299.e1. PubMed ID: 31705876
[No Abstract] [Full Text] [Related]
2. The Evolution of Acquired Resistance to BRAF
Xu G; Luo Y; Wu W; Liu X; Yu X; Bao Y; He X; Yu J; Li Y; Yang J; Zhang R; Yu C; Chen H; Xu J; Hu J; Jing J; Shi H
J Invest Dermatol; 2022 Feb; 142(2):445-458. PubMed ID: 34358527
[TBL] [Abstract][Full Text] [Related]
3. Targeting p63 Upregulation Abrogates Resistance to MAPK Inhibitors in Melanoma.
Patel A; Garcia LF; Mannella V; Gammon L; Borg TM; Maffucci T; Scatolini M; Chiorino G; Vergani E; Rodolfo M; Maurichi A; Posch C; Matin RN; Harwood CA; Bergamaschi D
Cancer Res; 2020 Jun; 80(12):2676-2688. PubMed ID: 32291316
[TBL] [Abstract][Full Text] [Related]
4. An epitranscriptomic mechanism underlies selective mRNA translation remodelling in melanoma persister cells.
Shen S; Faouzi S; Bastide A; Martineau S; Malka-Mahieu H; Fu Y; Sun X; Mateus C; Routier E; Roy S; Desaubry L; André F; Eggermont A; David A; Scoazec JY; Vagner S; Robert C
Nat Commun; 2019 Dec; 10(1):5713. PubMed ID: 31844050
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of BCL2 Family Members Increases the Efficacy of Copper Chelation in BRAF
Kim YJ; Tsang T; Anderson GR; Posimo JM; Brady DC
Cancer Res; 2020 Apr; 80(7):1387-1400. PubMed ID: 32005716
[TBL] [Abstract][Full Text] [Related]
6. BRAF exon 11 mutant melanoma and sensitivity to BRAF/MEK inhibition: Two case reports.
Melin A; Routier E; Tissot H; Rouleau E; Robert C
Eur J Cancer; 2019 Nov; 121():109-112. PubMed ID: 31569065
[No Abstract] [Full Text] [Related]
7. T-Type Calcium Channels as Potential Therapeutic Targets in Vemurafenib-Resistant BRAF
Barceló C; Sisó P; Maiques O; García-Mulero S; Sanz-Pamplona R; Navaridas R; Megino C; Felip I; Urdanibia I; Eritja N; Soria X; Piulats JM; Penin RM; Dolcet X; Matías-Guiu X; Martí RM; Macià A
J Invest Dermatol; 2020 Jun; 140(6):1253-1265. PubMed ID: 31877318
[TBL] [Abstract][Full Text] [Related]
8. Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors.
Ming Z; Lim SY; Kefford RF; Rizos H
Pigment Cell Melanoma Res; 2020 Mar; 33(2):345-357. PubMed ID: 31518489
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of Resistance to BRAF-Targeted Melanoma Therapies.
Dulgar O; Kutuk T; Eroglu Z
Am J Clin Dermatol; 2021 Jan; 22(1):1-10. PubMed ID: 33368052
[TBL] [Abstract][Full Text] [Related]
10. The Blood Brain Barrier and BRAF inhibitors: Implications for patients with melanoma brain metastases.
Smalley KSM; Forsyth PA
Pharmacol Res; 2018 Sep; 135():265-267. PubMed ID: 29146209
[No Abstract] [Full Text] [Related]
11. Noncanonical EphA2 Signaling Is a Driver of Tumor-Endothelial Cell Interactions and Metastatic Dissemination in BRAF Inhibitor‒Resistant Melanoma.
Zhang C; Smalley I; Emmons MF; Sharma R; Izumi V; Messina J; Koomen JM; Pasquale EB; Forsyth PA; Smalley KSM
J Invest Dermatol; 2021 Apr; 141(4):840-851.e4. PubMed ID: 32890629
[TBL] [Abstract][Full Text] [Related]
12. Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma.
Brummer C; Faerber S; Bruss C; Blank C; Lacroix R; Haferkamp S; Herr W; Kreutz M; Renner K
Cancer Lett; 2019 Feb; 442():453-463. PubMed ID: 30481565
[TBL] [Abstract][Full Text] [Related]
13. BRAFi induced demethylation of miR-152-5p regulates phenotype switching by targeting TXNIP in cutaneous melanoma.
Li K; Tang M; Tong S; Wang C; Sun Q; Lv M; Sun X; Wang T; Jin S
Apoptosis; 2020 Apr; 25(3-4):179-191. PubMed ID: 32056038
[TBL] [Abstract][Full Text] [Related]
14. Impact of BRAF kinase inhibitors on the miRNomes and transcriptomes of melanoma cells.
Kozar I; Cesi G; Margue C; Philippidou D; Kreis S
Biochim Biophys Acta Gen Subj; 2017 Nov; 1861(11 Pt B):2980-2992. PubMed ID: 28408301
[TBL] [Abstract][Full Text] [Related]
15. Combination with γ-secretase inhibitor prolongs treatment efficacy of BRAF inhibitor in BRAF-mutated melanoma cells.
Zhu G; Yi X; Haferkamp S; Hesbacher S; Li C; Goebeler M; Gao T; Houben R; Schrama D
Cancer Lett; 2016 Jun; 376(1):43-52. PubMed ID: 27000992
[TBL] [Abstract][Full Text] [Related]
16. Contextual role of E2F1 in suppression of melanoma cell motility and invasiveness.
Meng P; Bedolla RG; Yun H; Fitzpatrick JE; Kumar AP; Ghosh R
Mol Carcinog; 2019 Sep; 58(9):1701-1710. PubMed ID: 31124185
[TBL] [Abstract][Full Text] [Related]
17. Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents.
Rossi A; Roberto M; Panebianco M; Botticelli A; Mazzuca F; Marchetti P
Eur J Pharmacol; 2019 Nov; 862():172621. PubMed ID: 31446019
[TBL] [Abstract][Full Text] [Related]
18. Overcoming the resistance to BRAF inhibitor by the double BRAF and MEK inhibitions in advanced melanoma: a case report.
Kattan J; Kattan C; Farhat F; Assi T
Anticancer Drugs; 2019 Nov; 30(10):1052-1054. PubMed ID: 31490286
[TBL] [Abstract][Full Text] [Related]
19. A rare BRAF T599dup mutation conferring sensitivity to BRAF inhibitor in a patient with metastatic melanoma.
Marchand A; Tallet A; Collin C; Cormier B; Venel Y; Miquelestorena-Standley E; Machet L
Br J Dermatol; 2018 Aug; 179(2):528-529. PubMed ID: 29494756
[No Abstract] [Full Text] [Related]
20. The Tumor-Promoting Role of TRIP4 in Melanoma Progression and its Involvement in Response to BRAF-Targeted Therapy.
Hao J; Xu H; Luo M; Yu W; Chen M; Liao Y; Zhang C; Zhao X; Jiang W; Hou S; Feng X; Zou K; Chen Y; Huang W; Guo W; Kang L; Deng W
J Invest Dermatol; 2018 Jan; 138(1):159-170. PubMed ID: 28899685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
